Advertisement

Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease

      Abstract

      The effect of xuezhikang on postprandial triglyceride (TG) level was investigated in patients with coronary heart disease (CHD) after a high-fat meal (800 cal; 50 g fat). Fifty CHD patients were randomly divided into two groups to accept xuezhikang (xuezhikang group) 1200 mg/day (600 mg twice daily) or not (control group) on the base of routine therapy which included aspirin, metoprolol and fosinopril and nitrates during the whole 6 weeks following-up. Xuezhikang significantly reduced fasting serum total cholesterol (TC) (−20%), low-density lipoprotein cholesterol (LDL-C, −34%), TG (−32%) and apoB (−27%) levels, and raised fasting high-density lipoprotein cholesterol (HDL-C, 18%) and apoA-I (13%) levels (P<0.001). The postprandial serum TG levels at 2, 4 and 6 h decreased 32, 38 and 43%, respectively, in xuezhikang group (P<0.001). The TG area under the curve over the fasting TG level (TG-AUC) significantly decreased in CHD patients accepted xuezhikang with normal (less than 1.7 mmol/l) and elevated (1.74 to 2.92 mmol/l) fasting TG levels by 45 and 50%, respectively (P<0.001). Routine therapy had no significant effect on the fasting and postprandial lipid and apolipoprotein levels. The change of TG-AUC was significantly related to the changes of fasting TG, TC, LDL-C, and HDL-C levels after the treatment, which were related to the changes of fasting apoA-I and apoB levels significantly (P<0.001). Xuezhikang was shown to be beneficial in the treatment of reflecting postprandial triglyceridemia in CHD patients with normal and mildly elevated fasting TG levels.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ericsson C.G.
        • Hamsten A.
        • Nilsson J.
        • Grip L.
        • Svane B.
        • de Faire U.
        Angiographic assessment of effects of bezafibrate on progression of coronary heart disease in young male postinfarction patients.
        Lancet. 1996; 347: 849-853
        • Assmann G.
        • Schulte H.
        • von Eckardstein A.
        Hypertriglyceridaemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men.
        Am. J. Cardiol. 1996; 77: 1179-1184
        • Assmann G.
        • Cullen P.
        • Schulte H.
        • The Munster Heart Study (PROCAM)
        Results of follow-up at 8 years.
        Eur. Heart J. 1998; 19: A2-A11
        • Hokanson J.E.
        • Austin M.A.
        Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.
        J. Cardiovasc. Risk. 1996; 3: 213-219
        • Zilversmit D.B.
        Atherogenesis: a postprandial phenomenon.
        Circulation. 1979; 60: 473-485
        • Groot P.H.
        • van Stiphout W.A.
        • Krauss X.H.
        • Jansen H.
        • Vantol A.
        • Van Ramshorst E.
        • Chinon S.
        • Hofman A.
        • Cresswell S.R.
        • Havekes L.
        Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease.
        Arterioscler. Thromb. 1991; 11: 653-662
        • Weintraub M.S.
        • Grosskopf I.
        • Rassin T.
        • Miller H.
        • Charach G.
        • Rotmensch H.H.
        • Liron M.
        • Rubinstein A.
        • Iaina A.
        Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over 3 years.
        Br. Med. J. 1996; 312: 936-939
        • Slyper A.H.
        A fresh look at the atherogenic remnant hypothesis.
        Lancet. 1992; 340: 289-291
        • Doi H.
        • Kugiyama K.
        • Ohgushi M.
        • Sugiyama S.
        • Matsumura T.
        • Ohta Y.
        • Nakano T.
        • Nakajima K.
        • Yasue H.
        Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation.
        Atherosclerosis. 1998; 137: 341-349
        • Grieve D.J.
        • Avella M.A.
        • Elliott J.
        • Botham K.M.
        The influence of chylomicron remnants on endothelial cell function in the isolated perfused rat aorta.
        Atherosclerosis. 1998; 139: 273-281
        • Patsch J.R.
        • Miesenbock G.
        • Hopferwieser T.
        • Mühlberger V.
        • Knapp E.
        • Dunn J.K.
        • Gotto A.M.
        • Patsch W.
        Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state.
        Arterioscler. Thromb. 1992; 12: 1336-1345
        • Silveira A.
        • Karpe F.
        • Blomback M.
        • Steiner G.
        • Walldius G.
        • Hamsten A.
        Activation of coagulation factor VII during alimentary lipemia.
        Arterioscler. Thromb. 1994; 14: 60-69
        • Zhao S.P.
        • Liu L.
        • Gao M.
        • Zhou Q.C.
        • Li Y.L.
        • Xia B.
        Impairment of endothelial function after a high-fat meal in patients with coronary artery disease.
        Coron. Artery Dis. 2001; 12: 561-565
        • Cullen P.
        Evidence that triglycerides are an independent coronary heart disease risk factor.
        Am. J. Cardiol. 2000; 86: 943-949
        • Sheu W.H.
        • Jeng C.Y.
        • Lee W.J.
        • Lin S.Y.
        • Pei D.
        • Chen Y.T.
        Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia.
        Metabolism. 2000; 50: 355-359
        • Battula S.B.
        • Fitzsimons O.
        • Moreno S.
        • Owens D.
        • Collins P.
        • Johnson A.
        • Tomkin G.H.
        Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism.
        Metabolism. 2000; 49: 1049-1054
        • Isusi E.
        • Aspichueta P.
        • Liza M.
        • Hernandez M.L.
        • Diaz C.
        • Hernandez G.
        • Martinez M.J.
        • Ochoa B.
        Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes.
        Atherosclerosis. 2000; 153: 283-294
        • Heber D.
        • Yip I.
        • Ashley J.M.
        • Elashoff D.A.
        • Elashoff R.M.
        • Go V.L.
        Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement.
        Am. J. Clin. Nutr. 1999; 69: 231-236
        • Kou W.R.
        • Lu Z.L.
        • Guo J.X.
        • Li H.Y.
        • Xue S.W.
        • Lin Y.Z.
        • Wu X.S.
        • Chen H.
        Effect of xuezhikang on the treatment of primary hyperlipidemia.
        Zhonghua Nei Ke Za Zhi. 1997; 36: 529-531
        • Jian J.B.
        • Hao X.Y.
        • Deng C.Q.
        • Zhou H.T.
        • Lin J.
        The effects of Xuezhikang on serum lipid profile, thromboxane A(2) and prostacyclin in patients with hyperlipoidemia.
        Zhonghua Nei Ke Za Zhi. 1999; 38: 517-519
        • Keithley J.K.
        • Swanson B.
        • Sha B.E.
        • Zeller J.M.
        • Kessler H.A.
        • Smith K.Y.
        A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia.
        Nutrition. 2002; 18: 201-204
        • Vigna G.B.
        • Donega P.
        • Passaro A.
        • Zanca R.
        • Cattin L.
        • Fonda M.
        • Pauciullo P.
        • Marotta P.
        • Weintraub M.S.
        • Charach G.
        • Grosskopf I.
        Effects of fibric acid derivatives and metformin on postprandial lipemia.
        Atherosclerosis. 1998; 141: S71-S75
        • Vigna G.B.
        • Donega P.
        • Passaro A.
        • Zanca R.
        • Cattin L.
        • Fonda M.
        • Pauciullo P.
        • Marotta G.
        • Fellin R.
        • Gasparrini S.
        • Piliego T.
        Post-prandial effects of gemfibrozil vs. simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
        Nutr. Metab. Cardiovasc. Dis. 1999; 9: 234-243
        • O'Keefe Jr, J.H.
        • Harris W.S.
        • Nelson J.
        • Windsor S.L.
        Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia.
        Am. J. Cardiol. 1995; 76: 480-484
        • Westphal S.
        • Orth M.
        • Ambrosch A.
        • Osmundsen K.
        • Luley C.
        Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids.
        Am. J. Clin. Nutr. 2000; 71: 914-920
        • Jones P.
        • Kafonek S.
        • Laurora I.
        • Hunninghake D.
        Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study).
        Perfusion. 1998; 11: 202-208
        • Weintraub M.S.
        • Eisenberg S.
        • Breslow J.L.
        Lovastatin reduces postprandial lipoprotein levels in hypercholesterolaemic patients with mild hypertriglyceridaemia.
        Eur. J. Clin. Invest. 1989; 19: 480-485
        • Simo I.E.
        • Yakichuk J.A.
        • Ooi T.C.
        Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome.
        Atherosclerosis. 1993; 100: 55-64
        • Stein E.A.
        • Lane M.
        • Laskarrzewski P.
        Comparison of statins in typertriglyceridmia.
        Am. J. Cardiol. 1998; 81: B66-B69